Here, we show that combination therapy with Entinostat plus NHS-rmIL12 elicits significant survival benefit in murine models with a range of immunogenicity and sensitivity to PD-L1 blockade, namely poorly immunogenic EMT6 breast tumors, and MC38 and CT26 colon carcinoma models. Here, CD274 is linked to colon carcinoma.